Boston Biomedica, Inc.
This article was originally published in The Gray Sheet
Executive SummaryAssets of wholly owned esoteric clinical reference lab subsidiary BBI Clinical Labs are purchased by Specialty Labs of Santa Monica, California for $9.5 mil. cash. The deal, announced Feb. 20, adds BBICL's expertise in Lyme disease and tick-borne pathogens and immunological/molecular analysis of HIV and viral hepatitis to Specialty's more than 3,500 clinical reference lab test offerings. Transaction includes transitional services agreement under which Bridgewater, Massachusetts-based BBI will support the integration of the divested unit over the remainder of 2001
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.